<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109128">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01729364</url>
  </required_header>
  <id_info>
    <org_study_id>vätskestudien</org_study_id>
    <nct_id>NCT01729364</nct_id>
  </id_info>
  <brief_title>Fluid Investigation Colloid vs Crystalloid Reg. Renal Hemodynamics and Function</brief_title>
  <official_title>Colloid vs Crystalloid Infusion Postoperative in CABG Patients Regarding Renal Hemodynamics and Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <authority>Sweden: Swedish Research Council</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing the effects of crystalloid versus colloid fluid resuscitation in CABG patients
      postoperatively regarding renal blood flow, glomerular filtration rate and renal oxygen
      demand.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to blood loss and SIRS postoperative hypovolemia is a usual feature after CABG surgery.
      Substantial controversy persists regarding the best choice of fluid to be used for
      resuscitation in this setting regarding renal function and oxygen supply-demand matching. In
      our study we aim to investigate differences in functional renal parameters by dividing
      hypovolemic patients postoperatively in two groups, substituted either with crystalloid
      fluid, Ringer-Acetat, 20 ml/kg or colloid, HES 6% (130/0,4) 10 ml/kg under 20 minutes.
      Central and renal hemodynamics will be measured before (baseline) and after fluid
      administration by blood sampling and thermodilution in both pulmonary artery catheter and
      renal vein catheter. Measurement endpoints will mainly consist of central hemodynamics,
      renal blood flow, GFR and renal oxygen extraction rate which we aim to compare between
      groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change from baseline and differences inbetween groups in glomerular filtration rate, measured at different timepoints</measure>
    <time_frame>125min after baseline-measures</time_frame>
    <safety_issue>No</safety_issue>
    <description>GFR measured by thermodilution and blood- and urine sampling baseline1 (0min), baseline2 (+30min), timepoint1 (+65min), tp2 (+85min), tp3 (+105min), tp4 (+125min)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>crystalloid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>crystalloid fluid administration, Ringer-acetat 20ml/kg under 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>colloid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>colloidal fluids administration, HES 6% (130/0,4)  7ml/kg under 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crystalloid</intervention_name>
    <arm_group_label>crystalloid</arm_group_label>
    <other_name>Ringer Lactate</other_name>
    <other_name>NaCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colloid</intervention_name>
    <arm_group_label>colloid</arm_group_label>
    <other_name>Voluven</other_name>
    <other_name>Venofundin</other_name>
    <other_name>Tetraspan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective fast track CABG patients, postoperative

        Exclusion Criteria:

          -  hemodynamic instability

          -  preoperative renal impairment

          -  major postoperative bleeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vitus Krumbholz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Skytte Larson, MD</last_name>
    <phone>0046-313429804</phone>
    <email>jenny.skytte@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <phone>0046-313427433</phone>
    <email>sven-erik.ricksten@aniv.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital/Thoracic Intensive Care</name>
      <address>
        <city>Göteborg</city>
        <state>Västra Götaland</state>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Skytte, MD</last_name>
      <phone>0046-313429804</phone>
      <email>jenny.skytte@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Vitus Krumbholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 1, 2013</lastchanged_date>
  <firstreceived_date>November 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Vitus Krumbholz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>elective CABG</keyword>
  <keyword>renal impairment</keyword>
  <keyword>GFR</keyword>
  <keyword>renal blood flow</keyword>
  <keyword>colloid</keyword>
  <keyword>crystalloid</keyword>
  <keyword>thermodilution technique</keyword>
  <keyword>oxygen supply demand</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
